Fat loss research encompasses multiple mechanistic axes — GLP-1/GIP/glucagon receptor agonism (appetite/energy), growth hormone axis lipolysis, adipose-targeted apoptosis, and thyroid axis modulation. QSC supplies research-grade compounds across all these pathways. This guide organises the QSC catalog by mechanism for researchers designing fat loss studies.
Tirzepatide and retatrutide have the highest magnitude of weight reduction in published trials (15-24%). GLP-1R agonists are the most clinically validated class. AOD-9604 and adipotide have preclinical fat loss data with distinct mechanisms.
What is the difference between GLP-1R and GH-axis fat loss mechanisms?
GLP-1R agonists act centrally on appetite (arcuate nucleus, NTS) and peripherally on gastric emptying and insulin secretion. GH axis compounds (AOD-9604, tesamorelin) act peripherally on adipocyte lipolysis via beta-adrenergic/HSL pathways. Both reduce fat mass but through independent mechanisms that can be studied in combination.
What is the research value of triple agonists like retatrutide?
Triple agonists (GLP-1R + GIPR + GCGR) allow study of combined receptor activation versus individual axes. Retatrutide produced 24.2% weight reduction in Phase 2 — substantially above dual or mono agonists — making it the reference compound for maximum-efficacy incretin receptor combination research.
What formats does QSC supply these compounds in?
All GLP-1/GIP/GH axis compounds supplied as lyophilised research vials or where noted as multi-dose preparations. ≥99% HPLC purity, Janoshik COA. Ships from domestic warehouses in USA, EU, UK, Canada, and Australia.
